Multiple sclerosis (MS) is one of the commonest causes of chronic neurological disability in young and middle-aged adults. In the UK about 80 000 people have MS. There are some 2500 newly diagnosed cases per year and the average general practitioner (GP) will have three MS patients in the practice; this equates to some 130 patients in every primary care group. MS is seldom diagnosed under 10 or after 59 years of age. The mean age of onset is in the third and fourth decades with a peak at 25±30 years. MS is commoner in females, and Caucasians are considerably more susceptible than Asians or Blacks. The aetiology of MS is not fully understood. There could be a relationship between environmental factorsÐlatitude, urbanization and hygiene (all dif®cult to quantify)Ðand genetic predisposition.
Although much has been done to advance the cause of people with MS, services for them and their carers still leave much to be desired. MS resources vary considerably; in some places excellence prevails, in others it does not. Recently introduced medications for MS may have increased this inequality, because access to them varies between health regions. This paper seeks to de®ne what is needed to enhance MS services to an acceptable level throughout the UK.
CLINICAL CHARACTERISTICS AND CLASSIFICATION
MS usually begins at a time when it can have great impact on work, family and social life. It is unpredictable in terms of disability development and occurrence of attacks. There is a tendency to progressive disability, and over time the needs of the patient change. No concise boundary lines exist but`types' of MS are conventionally recognized (Figure 1 Benign (15±20% of patients)
In some patients a long interval elapses between ®rst diagnosis of MS and signi®cant incapacityÐi.e. disease progression is very slow. Furthermore, typical MS lesions have been found at necropsy in patients who have had only isolated neurological abnormalities during their lives; hence there is some pathological evidence for a`benign' classi®cation.
Relapsing±remitting (about 30% of patients)
Patients have symptoms that last for several weeks and then seem to disappear only to reappear later. After a period, these too resolve. Recovery from each relapse may seem complete, or the patient may be left with a residual disability.
Secondary progressive (about 40% of patients)
In these patients the course of MS changes from a relapsing and remitting pattern to a progressive phase where deterioration occurs irrespective of relapses, recovery from which is often incomplete. The time from clinical onset to the development of progression varies, but is usually 10±15 years.
Primary progressive (10±15% of patients)
From onset, there is a steady disease progression and, although relapses may occur, deterioration continues unabated. Primary progressive MS is seen in about threequarters of patients who present over the age of 50 (some 15% of the patient population).
There is debate concerning overlap between the classi®cations which is why the ®gures do not add up to 100%.
MANAGEMENT

Diagnostic phase
GPs will frequently be consulted about symptoms that suggest MS, and an established referral route is needed when their`index of suspicion' dictates. Ideally, patients should see a neurologist within 4 weeks (it is often several months), since the wait can be stressful for them and their families.
No speci®c diagnostic test is available for MS. The judgment of a consultant neurologist is essential for accurate diagnosis. A positive diagnosis begins from identi®cation of two or more lesions in the central nervous system (CNS) dissociated in both space and time. Various criteria have been drawn up to assist in this process but none covers every case seen. The criteria from Poser 2 have been used almost universally for research studies.
Magnetic resonance imaging (MRI) provides a highly sensitive technique for displaying CNS lesions 3 , and when these are in different regions of the brain it adds to the evidence provided by application of the Poser criteria. MRI is not mandatory for diagnosis; when scans are performed they must be interpreted by an experienced radiologist to prevent misdiagnosis.
Cerebrospinal¯uid (CSF) studies are also useful in diagnosis: oligoclonal bands, present in CSF but not seen in plasma, are found in 95% of`clinically de®nite' MS patients; where the diagnosis is less certain, abnormal bands are found much less frequently. If CSF studies and MRI are both negative, this can be a useful pointer to non-MS status.
The interval between completion of tests and communication of the results to an anxious patient should be as short as possible. Disclosure of the diagnosis to a patient and his or her relatives is a complex process, and to the recipients of such news it is a major`life event'. Clinicians are unlikely to have the time (ideally 30±60 minutes) they would wish to spend with a newly diagnosed patient; an MS specialist nurse and the MS charities may be able to help 4, 5 .
MS specialist nurses in the UK are few. In 1998, within the NHS there were some 20 clinical nurse specialists and 40 neurology clinical nurse specialists (who likewise care for patients with MS); 25 more MS nurses were ®nanced by the pharmaceutical industry.
Minimal impairment phase
At ®rst, many people diagnosed as having MS will be able to perform most of the tasks of daily living despite symptoms such as fatigue, sensory disturbances and bladder, bowel and sexual problems. They may not have come to terms with the diagnosis and can have dif®culty in envisaging their future. Avenues should be provided for patients and their families to receive advice on ®nancial planning, insurance, personal and inter-family relationships, employment problems, social security provisions and housing modi®cations. Patients will need prompt access to the neurologist for assessment if they have a relapse; medication may or may not be given and they need expert advice on symptom control. Some patients will have`researched' MS and will ask if certain drugs are available 6 .
Moderate impairment phase
Disability is now greater and frequent short-term admissions may be necessary to manage relapses. Services should bē exible and as seamless as possible, and response times should be short. Effective management requires a multidisciplinary approach. Many patients are not aware of the speci®c skills and availability of a multidisciplinary support team.
Ideally the support team should be locally based to ensure rapid and ef®cient communication not just with the patient but between all medical and care agencies. In some instances, a period of inpatient rehabilitation will be bene®cial to address complex symptoms in a coordinated and intensive manner. Equipment such as walking-sticks, wheelchairs and stairlifts should be available locally and not from a distant centre. Waiting time for assessment and provision of simple aids should not exceed 4 weeks.
Severe disability phase
In this phase the patient is likely to be dependent in all aspects of daily living including personal care. Meeting the needs of carers is of almost equal importance.
There is potential for secondary complications such as pressure sores and contractures, with their implications for mobility. The toll on district nurses is heavy 7 and they will 220 
Rehabilitation
Patients with substantial disability require easy access to rehabilitation teams. Few neurologists are able to devote much time to rehabilitation 8 . At all times in the rehabilitation process it should be emphasized that longterm disability is not synonymous with illness. Advice from nurses, occupational therapists, physiotherapists, speech therapists and dietitians should be an integral part of the package offered to MS patients and carers 9 . Well administered rehabilitation programmes can be of great bene®t to patients 10±12 .
Non-symptomatic therapies
Until recently, no drug was shown on systematic investigation to be ef®cacious against MS. The following are now being used or being investigated.
Copolymer-1 (glatiramer acetate)
It is now several decades since copolymer-1 (licensed in the USA but not yet in the UK) was shown to suppress and block acute and chronic-relapsing experimental allergic encephalomyelitis. More recently it has been shown to reduce the relapse rate in patients with relapsing±remitting MS. Neurological impairment has been favourably affected and patients have been shown to tolerate treatment (by subcutaneous injection) well, although injection site reactions occur. Its ef®cacy is maintained in the long term.
Corticosteroids
Corticosteroids accelerate recovery from an acute exacerbation but have not been shown to affect long-term disability.
Immunosuppressants
Azathioprine, cyclophosphamide and cyclosporin offer only modest bene®ts and have extensive side-effects. According to the British Society of Rehabilitation Medicine, these drugs have no routine place in the management of progressive MS.
Immunoglobulins
Bene®cial effects of immunoglobulins on relapse rates and disability have not been impressive and, even with screening, some believe that there remains a small risk of hepatitis C contamination.
The interferons
Type 1 interferons, alpha and beta, are produced by macrophages, ®broblasts and endothelial cells. Of the beta interferons, 1a and 1b have been shown to have most bene®t in MS but their precise mode of action is still open to conjecture. They alter the natural course of relapsing± remitting MS and have been successfully employed in secondary progressive MS, reducing relapse rates over a 30month follow-up.
Although the interferons and glatiramer acetate have been shown to have bene®cial effects in MS their utilization in the UK (less so in Europe and the US) remains open to debate 13 . They are expensive, and the current debate centres on whether money could be better spent elsewhere e.g. on specialist nurse support. The voluntary sector argues strongly that this is unfair and that people with MS deserve access to all services.
It takes many years to collect useful data concerning the disease process in MS; thus, outside clinical trials used for licensing, we have very limited data. Because prescribing at present is highly controlled, further data collection is slow. Future policy is likely to be decided by the National Institute for Clinical Excellence (NICE), which is due to report on this matter during 2000.
Symptom management
Fatigue Fatigue is a common complaint in MS patients 14 . It can be profoundly disabling and may demand much rearrangement of a patient's life. Amantidine and pemoline have been used with only moderate success. Fatigue management programmes designed by occupational therapists may be helpful.
Urinary, bowel and sexual disorders
About three-quarters of MS patients have bladder disorders, the commonest being frequency and urgency of micturition (85%), urge incontinence (63%) and hesitancy and interrupted stream (45%) 15 . Medication includes oxybutynin, capsaicin and desmopressin but these agents have sideeffects and dosage must be carefully supervised. Many patients have been greatly helped and have had dignity restored by the introduction of clean intermittent selfcatheterization. Sexual dif®culties in women are frequently related to bladder troubles, tiredness and depression. Impotence in men may be addressed with alprostadil or by use (not on the data sheet) of phentolamine or papaverine. 
Spasticity
Spasticity is common, particularly in the progressive stages of MS. It is complex and often poorly managed 16 . Spasms can be painful and in mobile patients may result in falls; immobile patients may have considerable dif®culty in achieving comfortable seating positions. Treatment options include physiotherapy, medication and surgical procedures. Baclofen has been available for many years and may be given orally or, under specialized supervision, intrathecally 17 . Dantrolene, diazepam and vigabatrin are alternative regimens. Recently, tizanidine has proven ef®cacious. Sometimes peripheral chemical blockade with botulinum toxin, alcohol or phenol may be appropriate. The role of cannabis in the management of spasticity is under investigation.
Pain
Pain and dysaesthesia are now recognized as common in MS, occurring in up to 65% of patients 18 . Patients with pain tend to have a low score on mental health indices with adverse effects on performance at work and personal relationships.
Primary pain syndromes are the result of demyelination in sensory or motor pathways; secondary effects include the consequences of immobility, back pain and osteoporosis. In most cases the pain is chronic. Among acute pain syndromes trigeminal neuralgia is 300±400 times more common than in the general population. Acute pain also arises from tonic spasms, optic neuritis and the bladder. Therapies include amitriptyline, baclofen, carbamazepine, gabapentin, phenytoin and valproate. Rhizotomy, by alcohol or glycerol instillation, seems to work less well in MS than in other disorders.
Cognitive disorders
Some cognitive dysfunction is common in MS and may be present early in the disease 19 Ðmemory loss and problems with verbal¯uency/pronunciation, conceptual reasoning and visuospatial awareness.
Depression
As many as half of MS patients are found to have moderate to severe depression, which may exacerbate other disorders such as sexual dysfunction. Depression is commoner in MS than in other chronic neurological conditions 20 . It does not correlate with drug treatment, disease duration or degree of disability.
Visual disorders
About 10% of patients are visually impaired and qualify for registration as partially sighted or blind 21 . Fatigue can exacerbate visual troubles. The commonest are residual scotoma, diplopia and oscillopsia. There have been few published accounts of successful therapy for visual disorders.
Temperature sensitivity
Many MS patients are temperature sensitive, their symptoms worsening in hot weather or during exercise, bathing or even when taking a hot drink. Potassium blocking agents such as 4-aminopyridine have been employed to alleviate temperature sensitivity 22 .
Tremor
At ®rst presentation tremor is uncommon in MS, but with time it develops in 50±80%. Symptomatic management includes beta blockers, isoniazid, primidone, clonazepam and carbamazepine, and a recent study showed intravenous ondansetron to be effective 23 . Thalamic stimulation and surgical procedures such as stereotactic thalamotomy have been employed in tremor management.
The ideal MS team
For diagnosis and subsequent management each health district should assemble a dedicated MS team. The team should ideally include or have easy access to the following personnel with relevant facilities: consultant neurologist (with specialized knowledge of MS); neuroradiologist; MS specialist nurse; neuropsychologist; social worker; occupational therapist; neurophysiotherapist; dietitian; speech and language therapist. Assessment, education, advice and treatment is most effectively provided by a team of professionals who work together to assess the many and various interacting problems. Effective communication between all team members is crucial. An MS specialist nurse can assist in initiating and coordinating the necessary referrals.
A comprehensive document published in 1997 by the Multiple Sclerosis Society outlines extensive care aims for MS teams 24 .
Care in the community
Much`care in the community' is now provided under the auspices of social services. There is often a lack of coordination and a fragmentation of information and service provision between the primary health care team, the hospital and social services. The appointment of MS specialist nurses should lessen this confusion. The primary care health team must have at least a basic understanding of the clinical features, aetiology and prognosis of MS 25 . related losses in tax revenue. To these costs can be added welfare payments, prescription charge exemptions and community care grants. Overall costings in MS are dif®cult, not least because a high and varied proportion are from social services as opposed to`NHS'. Diagnosis costs of MS vary greatly and GP costs are based on average time for all consultations; probably MS consultations are longer than average. One investigation 26 into the costs of MS in the UK showed an annual burden of £1.2 billion of which the NHS assumed 13%. The investigation was concluded before the interferons became widely available, so drug costs were not a large element. If new drugs are able to lessen symptoms, to modify/reduce relapses, to facilitate an acceptable quality of life and to delay progression to disability, the savings may well outweigh the costs of the agents themselves.
In the UK, patients, purchasers and providers of services must work together to ensure that people with MS receive the best treatment and care within available resources 27, 28 .
Self-management and patient partnership
Patients with MS should be encouraged to take part in decision-making about their healthcare. MS is a condition in which both the disease process and the treatment interventions can impact on almost every aspect of the lifestyle of patient and family. The bene®ts of such à partnership' approach include improved satisfaction, increased adherence to treatment and management programmes and a tendency for patients to maintain control. MS patients can offer substantial personal knowledge and experience, and there is vast potential for effective partnerships with healthcare professionals. Sad to say, the Brunel Survey 6 found that the professionals rated their support level much higher than did MS patients.
Professional training
The delivery of high-quality services which meet the needs of the person with MS has training implications for a wide range of professionals. Outside the few specialized units it is dif®cult at present to ®nd staff with extensive experience and understanding of MS. Many skilled professionals still focus on their own agendasÐi.e. on the protocols and services they can provide. Training is required at all levels of service delivery to address this gap. It may best be achieved by established regional neuroscience centres acting as a focal point for provision of`expert advice' and up-todate information, not only to healthcare professionals but also to patients and carers. The provision of relevant education has become a key objective of two national charitiesÐThe Multiple Sclerosis Society of Britain and Northern Ireland, 25 Ef®e Rd, Fulham, London SW6 1EE; and MS Research Trust, Spirella Building, Bridge Road, Letchworth, Herts SG6 4ET.
CONCLUSION
Although many improvements have been made in the provision of care for people with multiple sclerosis, much more could be done to improve their welfare. Quality care still remains something of a lottery, and over-burdened staff with no specialized MS training are often the only source of assistance. Where a specialized service is available, it is likely that an early and accurate diagnosis will be conveyed to the family in question; that ef®cient liaison between professionals will ensure appropriate care at every stage of the disease; that communication will be two-way: that waiting times will be short; and that respite can be offered at suitable locations.
MS is a costly disease and so is its management. A family may suffer huge ®nancial loss over the years and new drugs that may modify the progress of the disease are currently expensive. Service and care planning must, in the future, fully involve patients and their families. Professionals alone are unlikely to design services that meet patients' needs.
